Timing of eculizumab therapy for C3 glomerulonephritis

Clinical Kidney Journal

Volumn 8, Issue 4, 2015, Pages 449-452

  Rodriguez Osorio, Laura ^a,b   Ortiz, Alberto ^a,b  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b Section of Nephrology   (Spain)

Author keywords

Complement; Dialysis; Eculizumab; Glomerulonephritis; Haemolytic uraemic syndrome

Indexed keywords

ECULIZUMAB;

ACUTE KIDNEY FAILURE; C3 GLOMERULONEPHRITIS; CLINICAL TRIAL (TOPIC); DRUG COST; DRUG MEGADOSE; GLOMERULONEPHRITIS; HEMODIALYSIS; HUMAN; IMMUNOTHERAPY; KIDNEY FUNCTION; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; REVIEW; TIME TO TREATMENT;

EID: 84942099699     PISSN: 20488505     EISSN: 20488513     Source Type: Journal    
DOI: 10.1093/ckj/sfv065     Document Type: Review

References (28)

1. Inman M, Prater G, Fatima H et al. Eculizumab induced reversal of dialysis dependent kidney failure from C3 glomerulonephritis. Clin Kidney J 2015; 8: 445-448
2. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000791/WC500054208.pdf (27 June 2015, date last accessed)
3. Manrique J, Cravedi P. Role of monoclonal antibodies in the treatment of immune-mediated glomerular diseases. Nefrologia 2014; 34: 388-397
4. Campistol JM, Arias M, Ariceta G et al. An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus document. Nefrologia 2013; 33: 27-45
5. Le Quintrec M, Lionet A, Kandel C et al. Eculizumab for treatment of rapidly progressive C3 glomerulopathy. Am J Kidney Dis 2015; 65: 484-489
6. Bomback AS, Smith RJ, Barile GR et al. Eculizumab for dense deposit disease and C3 glomerulonephritis. Clin J Am Soc Nephrol 2012; 7: 748-756
7. Ávila A, Vizcaíno B, Molina P et al. Remission of aHUS neurological damage with eculizumab. Clin Kidney J 2015; 8: 232-236
8. Kim JJ,Waller SC, Reid CJ. Eculizumab in atypical haemolyticuraemic syndrome allows cessation of plasma exchange and dialysis. Clin Kidney J 2012; 5: 34-36
9. Povey H, Vundru R, Junglee N et al. Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis. Clin Nephrol 2014; 82: 326-331
10. http://www.abstracts2view.com/asn-2012/view.php?nu= 5013&terms=&type=abstract (27 June 2015, date last accessed)
11. Sevinc M, Basturk T, Sahutoglu T et al. Plasma resistant atypical hemolytic uremic syndrome associated with a CFH mutation treated with eculizumab: A case report. J Med Case Rep 2015; 9: 92
12. Ohta T, Urayama K, Tada Y et al. Eculizumab in the treatment of atypical hemolytic uremic syndrome in an infant leads to cessation of peritoneal dialysis and improvement of severe hypertension. Pediatr Nephrol 2015; 30: 603-608
13. Aresmouk D. Severe case of thrombotic microangiopathy with a delayed diagnosis of atypical haemolytic uraemic syndrome successfully managed with eculizumab. EJCRIM 2015; 2: Doi: 10.12890/2015-000180
14. Rousset-Rouvière C, Cailliez M, Garaix F et al. Rituximab fails where eculizumab restores renal function in C3nef-related DDD. Pediatr Nephrol 2014; 29: 1107-1111
15. Thajudeen B, Sussman A, Bracamonte E. A case of atypical hemolytic uremic syndrome successfully treated with eculizumab. Case Rep Nephrol Urol 2013; 3: 139-146
16. Ohanian M, Cable C, Halka K. Eculizumab safely reverses neurologic impairment and eliminates need for dialysis in severe atypical hemolytic uremic syndrome. Clin Pharmacol 2011; 3: 5-12
17. Durán CE, Blasco M, Maduell F et al. Rescue therapy with eculizumab in a transplant recipient with atypical haemolyticuraemic syndrome. Clin Kidney J 2012; 5: 28-30
18. Baskin E, Gulleroglu K, Kantar A et al. Success of eculizumab in the treatment of atypical hemolytic uremic syndrome. Pediatr Nephrol 2015; 30: 783-789
19. Legendre CM, Licht C, Muus P et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013; 368: 2169-2181
20. Noris M, Remuzzi G. Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Curr Opin Nephrol Hypertens 2013; 22: 704-712
21. Zuber J, Fakhouri F, Roumenina LT et al. French Study Group for aHUS/C3G: Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol 2012; 8: 643-657
22. Fakhouri F, Delmas Y, Provot F et al. Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: An analysis of 19 cases. Am J Kidney Dis 2014; 63: 40-48
23. Pickering MC, D'Agati VD, Nester CM et al. C3 glomerulopathy: Consensus report. Kidney Int 2013; 84: 1079-1089
24. Rabasco-Ruiz C, Huerta-Arroyo A, Caro-Espada J et al. C3 glomerulopathies. A new perspective on glomerular diseases. Nefrologia 2013; 33: 164-170
25. Payette A, Patey N, Dragon-Durey MA et al. A case of C3 glomerulonephritis successfully treated with eculizumab. Pediatr Nephrol 2015; 30: 1033-1037
26. Berthe-Aucejo A, Sacquépée M, Fila Met al. Blockade of alternative complement pathway in dense deposit disease. Case Rep Nephrol 2014; 2014: 201568
27. Ozkaya O, Nalcacioglu H, Tekcan D et al. Eculizumab therapy in a patient with dense-deposit disease associated with partial lipodystropy. Pediatr Nephrol 2014; 29: 1283-1287
28. https://clinicaltrials.gov/(28 June 2015, date last accessed)